Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Takeover Mania is Coming!!! -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (17)	7/21/2005 8:12:33 PM
From: richardred	Read Replies (2) \| Respond to of 49

Harry: I know Wilder also made clear he feels the same.<g> Just a guess, witch was based on Abbott's strength in pain management. Also on Abbott's Humira forcast. I've seen stranger things happen, such as Oxy buying Iowa beef. > Worldwide sales of HUMIRA totaled $852 million in 2004 and $280 million in 2003 and are forecasted to be more than $1.3 billion in 2005. 2% royalties opposed to 5% is a lot of cash. Their is also favorable data on a new indication for Humira on Crohn's disease. >New Orleans, Louisiana, May 18, 2004 — New data presented this week at the Digestive Disease Week (DDW) annual meeting demonstrate that patients with moderate to severely active Crohn's disease treated with HUMIRA® (adalimumab) achieved remission and clinical response in two separate clinical trials. In one of the trials, a Phase III pivotal study designed to evaluate the efficacy and tolerability of HUMIRA to induce remission in patients with active Crohn's disease, treatment with HUMIRA induced a statistically significant increase in remission at four weeks compared to placebo You might remember their was no love lost between J & J and Amgen on their license agreement over Procrit. Astra Zeneca ownes over 10 million shares of CATG based on this agreement. Through the Collaboration Agreement and the Subscription Agreement, CAT and AstraZeneca UK have entered into a major strategic alliance for the joint discovery and development of human monoclonal antibody therapeutics, principally in the field of inflammatory disorders, including respiratory diseases. The innovative partnership structure of the alliance reflects each company’s leading position in its respective field and the growing importance of antibodies as therapeutics. The alliance will be co-funded and co-managed by AstraZeneca UK and CAT. The alliance will include a five-year discovery initiation phase during which AstraZeneca UK and CAT will jointly initiate a minimum of 25 discovery programmes. The committed joint research investment will be a minimum of US$175 million during this phase which the parties will fund 50:50. CAT will contribute the greater part of the resource in this discovery phase and expects to commit between 100 and 150 scientists per year to the programme at its peak, most if not all of which will come from existing resources. The principal focus of the discovery programmes will be in inflammatory disorders, however the research may extend to other therapeutic areas. Following the completion of the discovery phase AstraZeneca UK and CAT may each elect to continue funding programmes into development. If both parties so elect, the programme will be jointly funded until Clinical Proof of Concept (end of Phase IIb trials), unless either party opts-out earlier. GITY/RR (good investing to you!)